The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses
Abstract
Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARS-CoV infection in many countries. The CoV main protease (M(pro)), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV M(pro)s. It is expected that inhibitors targeting CoV M(pro)s could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Kao, R. Y., Tsui, W. H. W., Lee, T. S. W., Tanner, J. A., Watt, R. M., Huang, J.-D., Hu, L., Chen, G., Chen, Z., Zhang, L., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.07.013 · Cited by 156
Cited by
The SARS-CoV-2 main protease as drug target
Ullrich, S., & Nitsche, C. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127377 · Cited by 772
Structural biology of SARS-CoV-2 and implications for therapeutic development
Yang, H., & Rao, Z. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00630-8 · Cited by 548
Self-citationA noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
Ratia, K., Pegan, S., Takayama, J., Sleeman, K., Coughlin, M., Baliji, S., Chaudhuri, R., Fu, W., Prabhakar, B. S., Johnson, M. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805240105 · Cited by 507
Drug targets for corona virus: A systematic review
Medhi, B., Prajapat#, M., Sarma#, P., Shekhar#, N., Avti, P., Sinha, S., Kaur, H., Kumar, S., Bhattacharyya, A., Kumar, H., et al. (2020) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_115_20 · Cited by 496
Khan, S. A., Zia, K., Ashraf, S., Uddin, R., & Ul-Haq, Z. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1751298 · Cited by 337
Metadata
- Authors
- Yang, H., Bartlam, M., & Rao, Z.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-12-01
- Volume
- 12
- Issue
- 35
- Pages
- 4573-4590
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2040522635
- Cited by
- 185
- References
- 3
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses. https://app.cochat.ai/papers/10.2174/138161206779010369
- The paper
- Yang, H., Bartlam, M., & Rao, Z. (2006). Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses. Current Pharmaceutical Design. https://doi.org/10.2174/138161206779010369
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.